| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1af8df51ce24ca931ae718fb747f6aa0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-221 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-536 |
| filingDate |
2010-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37bd7c1d2da9b8c282f66131b3bafad3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81eccb425acbb973357285dced4e591e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07a53a8edec61105d549129fd80a4a87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a434585735235937c9b2cd639ef80c65 |
| publicationDate |
2011-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011026298-A |
| titleOfInvention |
Compound |
| abstract |
When detecting an antigen (lesion marker) present in a lesion site using a compound containing a single chain antibody portion, the lesion is caused by the binding between the antigen present in the lesion site and the single chain antibody portion. The amount of compound reaching the site is reduced, and a signal (background) is generated from the compound bound to the antigen outside the lesion site. As a result, it is difficult to detect a highly sensitive and high-contrast lesion, and there is a need for a compound that can eliminate this. A compound comprising a polymer represented by the general formula (1). L-Y-A (1) (wherein A is a single-chain antibody part and is a polypeptide comprising an antigen binding site. L is a linker part and a polypeptide comprising a protease cleavage site. Y is a peptide part, and consists of zero or more amino acids linking the single chain antibody part A and the linker part L. The linker part L is the N terminus of the peptide part Y or the N terminus of the single chain antibody part A. Connected to) [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11168139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019230868-A1 |
| priorityDate |
2009-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |